Finally, the combination entecavir and Tα1 was more effective than entecavir alone in improving ALT, HBV-DNA, HBeAg, and HBeAg seroconversion (64), and, although not significantly, showed a tendency to inhibit the development of hepatocellular carcinoma (HCC) in patients with HBV-related compensated cirrhosis (65). Here, GPT is linked to hepatocellular carcinoma.